Navigating the Jargon of Molecular Testing in Non-Hodgkin Lymphoma

Presented by:
Eric D. Hsi
Search for other papers by Eric D. Hsi in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 18: Issue 12.5
Online Publication Date:
07 Dec 2020
DOI:
https://doi.org/10.6004/jnccn.2020.5032
Restricted access

The many different subtypes of non-Hodgkin lymphoma can be distinguished by histopathology, immunophenotype, and underlying genetic abnormalities. Molecular testing is routinely used by pathologists for diagnosis and prognosis, and to aid in guiding therapy selection (targeted or nontargeted). The different tools and techniques used for molecular testing are based on abnormality type and tissue available.

Disclosures: Dr. Hsi has disclosed that he has received grant/research support from AbbVie, Inc. and Eli Lilly and Company, and honoraria from Miltenyi Biotech and Seattle Genetics, Inc.

Correspondence: Eric D. Hsi, MD, Department of Laboratory Medicine, Cleveland Clinic, 9500 Euclid Avenue, L-30, Cleveland, OH 44195. Email: hsie@ccf.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press; 2017.

  • 2.

    Horwitz SM, Ansell S, Ai WZ, et al. NCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas. Version 1.2021. Accessed October 20, 2020. Available at: NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Aukema SM, Reiner S, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319–2331.

  • 4.

    Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 2014;124:2354–2361.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Morschhauser F, Tilly H, Chaidos A, et al. Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma [abstract]. Blood 2019;134(Suppl 1):Abstract 123.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2020 by the National Comprehensive Cancer Network 2020
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
20 Dec 2020
Online Publication Date:
07 Dec 2020

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1096 271 111
PDF Downloads 352 44 2
EPUB Downloads 0 0 0